Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer.
dc.contributor.author | Bernstein, Jonathan M | |
dc.contributor.author | Kershaw, Lucy E | |
dc.contributor.author | Withey, Stephanie B | |
dc.contributor.author | Lowe, Natalie M | |
dc.contributor.author | Homer, Jarrod J | |
dc.contributor.author | Slevin, Nicholas J | |
dc.contributor.author | Bonington, Suzanne C | |
dc.contributor.author | Carrington, Bernadette M | |
dc.contributor.author | West, Catharine M L | |
dc.date.accessioned | 2015-03-19T11:32:44Z | en |
dc.date.available | 2015-03-19T11:32:44Z | en |
dc.date.issued | 2015-02-17 | en |
dc.identifier.citation | Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer. 2015: Oral Oncol | en |
dc.identifier.issn | 1879-0593 | en |
dc.identifier.pmid | 25700703 | en |
dc.identifier.doi | 10.1016/j.oraloncology.2015.01.013 | en |
dc.identifier.uri | http://hdl.handle.net/10541/346889 | en |
dc.description.abstract | Non-response to induction chemotherapy (IC) occurs in 30% of head and neck squamous cell carcinoma (HNSCC) and has been predicted by tumor plasma flow (Fp) derived by perfusion computed tomography. The present study was designed to test whether baseline tumor Fp determined by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) would predict IC response. | |
dc.language | ENG | en |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Oral oncology | en |
dc.title | Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer. | en |
dc.type | Article | en |
dc.contributor.department | University Department of Otolaryngology - Head & Neck Surgery, Manchester Academic Health Science Centre, University of Manchester. | en |
dc.identifier.journal | Oral Oncology | en |
html.description.abstract | Non-response to induction chemotherapy (IC) occurs in 30% of head and neck squamous cell carcinoma (HNSCC) and has been predicted by tumor plasma flow (Fp) derived by perfusion computed tomography. The present study was designed to test whether baseline tumor Fp determined by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) would predict IC response. |